Latest filings (excl ownership)
15-12B
Securities registration termination
25 Feb 19
EFFECT
Notice of effectiveness
22 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 19
POSASR
Automatic shelf registration (post-effective amendment)
15 Feb 19
POS AM
Prospectus update (post-effective amendment)
15 Feb 19
SC 14D9/A
Tender offer solicitation (amended)
15 Feb 19
SC TO-T/A
Third party tender offer statement (amended)
15 Feb 19
25-NSE
Exchange delisting
15 Feb 19
SC TO-T/A
Third party tender offer statement (amended)
6 Feb 19
SC 14D9/A
Tender offer solicitation (amended)
5 Feb 19
SC 14D9/A
Tender offer solicitation (amended)
1 Feb 19
SC TO-T/A
Third party tender offer statement (amended)
1 Feb 19
SC 14D9
Tender offer solicitation
17 Jan 19
SC TO-T
Third party tender offer statement
17 Jan 19
SC TO-C
Information about tender offer
8 Jan 19
SC14D9C
Written communication relating to third party tender offer
7 Jan 19
SC TO-C
Information about tender offer
7 Jan 19
8-K
Entry into a Material Definitive Agreement
7 Jan 19
8-K
Departure of Directors or Certain Officers
2 Jan 19
8-K
Regulation FD Disclosure
6 Dec 18
8-K
FDA Approves VitrakviĀ®Ā (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion1,2
27 Nov 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
8-K
Loxo Oncology Reports Third Quarter 2018 Financial Results
8 Nov 18
UPLOAD
Letter from SEC
23 Oct 18
8-K
Other Events
17 Sep 18
CORRESP
Correspondence with SEC
6 Sep 18
UPLOAD
Letter from SEC
22 Aug 18
S-8
Registration of securities for employees
9 Aug 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
8-K
Loxo Oncology Reports Second Quarter 2018 Financial Results
9 Aug 18
8-K
Departure of Directors or Certain Officers
14 Jun 18
8-K
Regulation FD Disclosure
4 Jun 18
10-Q
2018 Q1
Quarterly report
8 May 18
8-K
Loxo Oncology Reports First Quarter 2018 Financial Results
8 May 18
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Loxo Oncology, Inc.
8 Jan 20
SC 13D/A
Loxo Oncology, Inc.
15 Feb 19
SC 13D/A
Beneficial ownership report (amended)
15 Feb 19
4
Naarden Jacob Van
15 Feb 19
4
Nisha Nanda
15 Feb 19
4
Avi Z. Naider
15 Feb 19
4
TIMOTHY M MAYLEBEN
15 Feb 19
4
Lori Anne Kunkel
15 Feb 19
4
Steve Harr
15 Feb 19
4
Alan Fuhrman
15 Feb 19
4
Keith T. Flaherty
15 Feb 19
4
STEVE ELMS
15 Feb 19
4
Jennifer Burstein
15 Feb 19
4
Joshua H. Bilenker
15 Feb 19
SC 13G/A
Loxo Oncology, Inc.
14 Feb 19
SC 13G/A
Loxo Oncology, Inc.
13 Feb 19
SC 13G/A
Loxo Oncology, Inc.
12 Feb 19
SC 13G/A
Loxo Oncology, Inc.
11 Feb 19
SC 13G/A
Loxo Oncology, Inc.
11 Feb 19
SC 13G/A
Loxo Oncology, Inc.
8 Feb 19
SC 13G/A
Loxo Oncology, Inc.
6 Feb 19
4/A
Naarden Jacob Van
17 Jan 19
4/A
Joshua H. Bilenker
17 Jan 19
SC 13D
Loxo Oncology, Inc.
15 Jan 19
SC 13D/A
Loxo Oncology, Inc.
15 Jan 19
SC 13G/A
Loxo Oncology, Inc.
10 Jan 19
4
Nisha Nanda
2 Jan 19
4
Jennifer Burstein
2 Jan 19
4
Naarden Jacob Van
2 Jan 19
4
Joshua H. Bilenker
2 Jan 19
3
Nisha Nanda
2 Jan 19
4
Avi Z. Naider
17 Dec 18
4
Naarden Jacob Van
12 Dec 18
4
Jennifer Burstein
12 Dec 18
4
Joshua H. Bilenker
12 Dec 18
4
Naarden Jacob Van
28 Nov 18
4
Jennifer Burstein
28 Nov 18
4
Joshua H. Bilenker
28 Nov 18
4
Jennifer Burstein
5 Oct 18